Last reviewed · How we verify
Innohep (tinzaparin)
Tinzaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.
Tinzaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin. Used for Venous thromboembolism prophylaxis in patients undergoing general or orthopedic surgery, Treatment of acute deep vein thrombosis, Treatment of acute pulmonary embolism.
At a glance
| Generic name | Innohep (tinzaparin) |
|---|---|
| Also known as | Innohep |
| Sponsor | Ottawa Hospital Research Institute |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Factor Xa and thrombin (via antithrombin III enhancement) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Tinzaparin is derived from unfractionated heparin through controlled enzymatic depolymerization, resulting in a mixture of polysaccharide chains with molecular weights between 5,600 and 7,500 Da. It potentiates the inhibition of coagulation factors by antithrombin III, with a higher anti-Xa to anti-IIa activity ratio compared to unfractionated heparin, providing more predictable pharmacokinetics and allowing subcutaneous administration.
Approved indications
- Venous thromboembolism prophylaxis in patients undergoing general or orthopedic surgery
- Treatment of acute deep vein thrombosis
- Treatment of acute pulmonary embolism
- Thromboembolism prophylaxis in acutely ill medical patients
Common side effects
- Bleeding
- Heparin-induced thrombocytopenia (HIT)
- Injection site reactions
- Elevated liver enzymes
Key clinical trials
- Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis (PHASE3)
- AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia (PHASE3)
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial (PHASE2)
- LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention (PHASE4)
- Thromboprophylaxis in Lower Limb Immobilisation (PHASE3)
- STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis (PHASE4)
- Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention (PHASE3)
- TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Innohep (tinzaparin) CI brief — competitive landscape report
- Innohep (tinzaparin) updates RSS · CI watch RSS
- Ottawa Hospital Research Institute portfolio CI